Lake Success, NY, United States
Lake Success, NY, United States

Time filter

Source Type

News Article | March 1, 2017
Site: www.prnewswire.co.uk

Research Being Presented at ECR Demonstrates how VolparaEnterprise Software Helps Breast Imaging Providers Deliver High-Quality, Personalised Breast Screening VIENNA, March 1, 2017 /PRNewswire/ -- Volpara Solutions announced the European launch of Volpara®Enterprise™ 2.0 software, which helps breast imaging facilities deliver high quality, personalised breast screening, here at the European Congress of Radiology (ECR) meeting, March 1-5, 2017.  (Expo X1, Stand 32). VolparaEnterprise software delivers key performance indicators (KPIs) for hundreds of performance and quality metrics, including patient positioning, compression and equipment utilisation. VolparaEnterprise software provides continuous quality assurance and performance monitoring through dynamic, interactive dashboards feeding ConstantQuality metrics that are updated with every mammography or tomosynthesis (3D mammography) exam. VolparaEnterprise software, a Microsoft Azure – based solution, is fully integrated with VolparaDensity software, the most clinically validated 3D Density solution. Designed to support large or small enterprises, VolparaEnterprise software enables breast centres to perform rapid quality control checks that help optimise the productivity and efficiency of imaging resources. This in turn helps decrease costs through the reduction of retakes, increase employee effectiveness, and enhance the patient experience. Updates to VolparaEnterprise 2.0 software include new infographics and analytics tools to help improve understanding of resource utilization and performance and provide better understanding of their patient population and referral patterns: the new Technologist dashboard enables each radiographer to monitor her own performance and self-train to fix positioning and compression problems; the Lead Radiographer now sees a Quality Quadrant diagram that summarises patient positioning and compression performance by each radiographer, helping to identify training opportunities. Also, the broader use of infographics on each new role-specific "landing page" makes data quicker and easier to summarize and interpret. "Adding VolparaEnterprise software has enabled us to implement new quality processes that will help ensure that every woman's mammogram is the best that we can offer.  Being able to pull data that has been hidden, we're able to improve the practice's efficiencies and effectiveness, which will help improve outcomes.  We owe that to our patients," said Kathy Schilling, MD, Medical Director, Boca Raton Regional Hospital's Christine E. Lynn Women's Health & Wellness Institute in Florida. Volpara Solutions is showcasing its entire suite of quantitative breast imaging tools at ECR. The company's technology is currently in use in 35 countries, and more than 9 million women have had their breast density analysed using VolparaDensity software. The ability of analytics data from VolparaEnterprise software to help maintain accuracy and consistent quality in breast screening is the focus of numerous abstracts and educational sessions accepted for presentation at the ECR, including: About Volpara Solutions Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand (formerly Matakina Technology). Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalised measurements of density, patient-specific x-ray dose, breast compression, breast positioning and other factors designed to provide critical insight for breast imaging workflow. For more information, visit www.volparasolutions.com.


News Article | February 21, 2017
Site: www.prweb.com

A new digital breast tomosynthesis technique has the potential to reduce the rate at which women are called back for additional examinations without sacrificing cancer detection, according to a new study published online in the journal Radiology. In 2011, the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use with full-field digital mammography (FFDM) in breast imaging. DBT uses a scanner that rotates partially around the breast, providing individual images of thin layers of tissue. When used with FFDM, DBT has been shown to improve cancer detection and reduce callbacks for additional examinations. However, the combination of the two methods requires a second radiation exposure to the breast, while also slightly increasing the time a patient spends in breast compression. Researchers at Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute in Newark, Del., have been exploring a relatively new approach in which the DBT images are used to create a synthesized 2-D (s2D) compilation image. The method has the potential to render FFDM unnecessary. “The adoption of s2D mammography combined with DBT into screening programs would limit radiation exposure to the patient, and, on the basis of our results, may improve clinical performance,” said Jacqueline S. Holt, M.D., FACR, director of Breast Imaging at Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute. Dr. Holt and colleagues set out to compare the clinical performance of DBT-s2D with that of DBT-FFDM and FFDM alone. As part of a community oncology program dedicated to breast imaging, the researchers were able to study 78,810 screening mammograms performed from 2011 to 2016. In the study group, 32,076 women were screened with FFDM, 30,561 women were screened using DBT-FFDM and 16,173 women were screened using DBT-s2D. Performance was assessed by looking at recall rate, the cancer detection rate, and positive predictive value (PPV), or the ability to predict if an image-detected abnormality is cancer. The results were eye-opening. DBT-s2D’s recall rate was only 4.3 percent, compared with 5.8 percent for DBT-FFDM. Overall cancer detection rates were similar, but DBT-s2D detected 76.5 percent of invasive cancers, compared with 61.3 percent for DBT-FFDM. At 3.6 percent, the false positive rate for DBT-s2D was significantly lower than the 5.2 percent rate for DBT-FFDM. And the positive predictive value of biopsy for DBT-s2D was 40.8 percent, compared to 28.5 percent for DBT-FFDM. Dr. Holt described the findings as both encouraging and surprising, especially given the fact that, with DBT-s2D, the positive predictive value went up. “If synthesized 2-D imaging is performed, you’ll get equal or better patient outcomes and go to a lower radiation dose,” she said. “These findings could be a practice-changer globally.” The results of the study also suggest that adoption of s2D mammography combined with DBT into screening programs would reduce the number of false-positive findings—an important consideration in the age of value-based medicine. “The downstream cost reduction when women don’t need to be called back for additional imaging amounts to millions of healthcare dollars saved,” Dr. Holt said. Dr. Holt understands that radiologists may be wary of relying on the s2D image. Her advice for clinics is to gradually adopt the technology and track how they’re doing through an initial trial period during which the DBT-s2D approach is used side-by-side with the DBT-FFDM technique. “A lot of the controversy surrounding screening mammography is about false-positive findings,” Dr. Holt said. “With this method, we are addressing this issue, optimizing patient care and adding value.” “Clinical Performance of Synthesized Two-dimensional Mammography Combined with Tomosynthesis in a Large Screening Population.” Collaborating with Dr. Holt were Mireille P. Aujero, M.D., Sara C. Gavenonis, M.D., Ron Benjamin, D.O., and Zugui Zhang, Ph.D. Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs.rsna.org/journal/radiology) RSNA is an association of 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)


News Article | February 21, 2017
Site: www.eurekalert.org

OAK BROOK, Ill. - A new digital breast tomosynthesis technique has the potential to reduce the rate at which women are called back for additional examinations without sacrificing cancer detection, according to a new study published online in the journal Radiology. In 2011, the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use with full-field digital mammography (FFDM) in breast imaging. DBT uses a scanner that rotates partially around the breast, providing individual images of thin layers of tissue. When used with FFDM, DBT has been shown to improve cancer detection and reduce callbacks for additional examinations. However, the combination of the two methods requires a second radiation exposure to the breast, while also slightly increasing the time a patient spends in breast compression. Researchers at Christiana Care Health System's Helen F. Graham Cancer Center & Research Institute in Newark, Del., have been exploring a relatively new approach in which the DBT images are used to create a synthesized 2-D (s2D) compilation image. The method has the potential to render FFDM unnecessary. "The adoption of s2D mammography combined with DBT into screening programs would limit radiation exposure to the patient, and, on the basis of our results, may improve clinical performance," said Jacqueline S. Holt, M.D., FACR, director of Breast Imaging at Christiana Care Health System's Helen F. Graham Cancer Center & Research Institute. Dr. Holt and colleagues set out to compare the clinical performance of DBT-s2D with that of DBT-FFDM and FFDM alone. As part of a community oncology program dedicated to breast imaging, the researchers were able to study 78,810 screening mammograms performed from 2011 to 2016. In the study group, 32,076 women were screened with FFDM, 30,561 women were screened using DBT-FFDM and 16,173 women were screened using DBT-s2D. Performance was assessed by looking at recall rate, the cancer detection rate, and positive predictive value (PPV), or the ability to predict if an image-detected abnormality is cancer. The results were eye-opening. DBT-s2D's recall rate was only 4.3 percent, compared with 5.8 percent for DBT-FFDM. Overall cancer detection rates were similar, but DBT-s2D detected 76.5 percent of invasive cancers, compared with 61.3 percent for DBT-FFDM. At 3.6 percent, the false positive rate for DBT-s2D was significantly lower than the 5.2 percent rate for DBT-FFDM. And the positive predictive value of biopsy for DBT-s2D was 40.8 percent, compared to 28.5 percent for DBT-FFDM. Dr. Holt described the findings as both encouraging and surprising, especially given the fact that, with DBT-s2D, the positive predictive value went up. "If synthesized 2-D imaging is performed, you'll get equal or better patient outcomes and go to a lower radiation dose," she said. "These findings could be a practice-changer globally." The results of the study also suggest that adoption of s2D mammography combined with DBT into screening programs would reduce the number of false-positive findings -- an important consideration in the age of value-based medicine. "The downstream cost reduction when women don't need to be called back for additional imaging amounts to millions of healthcare dollars saved," Dr. Holt said. Dr. Holt understands that radiologists may be wary of relying on the s2D image. Her advice for clinics is to gradually adopt the technology and track how they're doing through an initial trial period during which the DBT-s2D approach is used side-by-side with the DBT-FFDM technique. "A lot of the controversy surrounding screening mammography is about false-positive findings," Dr. Holt said. "With this method, we are addressing this issue, optimizing patient care and adding value." "Clinical Performance of Synthesized Two-dimensional Mammography Combined with Tomosynthesis in a Large Screening Population." Collaborating with Dr. Holt were Mireille P. Aujero, M.D., Sara C. Gavenonis, M.D., Ron Benjamin, D.O., and Zugui Zhang, Ph.D. Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://radiology. ) RSNA is an association of 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)


News Article | February 21, 2017
Site: www.prweb.com

Although more than three-quarters of women strongly agree that getting regular mammograms is important, just over half actually follow through. Women cite many reasons why scheduling a mammogram is difficult, including high cost, lack of insurance, fear, discomfort, time off work, travel, and childcare. PURE mammography, located within the Smith Haven Mall, now makes mammograms easy for thousands of Long Island women, many of whom have never had this potentially life-saving exam. Medical Arts Radiology developed the concept believing that mammography should be as routine as shopping for clothes or food. The easier it is for women to get a mammogram, the more women will be routinely screened, and the more lives will be saved. At PURE mammography, there is no need for referrals, prescriptions or appointments. There is no out of pocket expense for insured women and low cost exams are available for the uninsured. All mammograms are performed in 3D, an innovative new technique that detects more invasive breast cancers and reduces false positives by up to 40%. If previous studies were performed at an outside facility, the PURE staff will help obtain them for comparison. Additional services include screening breast ultrasound and DEXA bone density exams. Results are available within 24 hours and soon will be accessible on Medical Arts Radiology’s patient portal. PURE mammography is not only about convenience, but also comfort. The site was created in collaboration with a world leader in spa design. Dr. Barry Morgenstern, Director of Breast Imaging at Medical Arts Radiology, explains: “We’ve created a space that’s inviting, relaxing and comfortable. The experience includes a beautiful lounge area, warm robes, beverages, and a staff not only well trained in breast imaging but also in hospitality. We want women to feel like their next mammogram is more like a day at the spa.” PURE mammography debuts a new Mammography Information System, called Ikonopedia. Women enter information about their personal and family history into an iPad tablet, which is not only archived for future visits, but also enables breast cancer risk assessment. The average woman has about a 10% lifetime risk of developing breast cancer. Women with greater than 20% lifetime risk are encouraged to speak with their doctor about additional screening options. PURE mammography is accredited by the American College of Radiology. Breast imaging specialists interpret all exams. More than 90% of women screened will get good news on their breast health. About 1 in 10 women will need additional testing, which can be performed at any of Medical Arts Radiology’s 7 Women’s Imaging Centers across Long Island. These full-service offices are recognized as breast imaging Centers of Excellence by the American College of Radiology. In summary, Dr. Morgenstern says: “We can’t prevent breast cancer. But if we find it early enough, the chance for cure is nearly 100%. Mammograms save lives. And, PURE is screening mammography made easy.” Pure mammography is a newly created division of Medical Arts Radiology. The goal of PURE mammography is to improve utilization of screening mammography by removing common barriers that prevent women from obtaining this potentially life-saving exam. Medical Arts Radiology has served patients and referring physicians with the latest advances in diagnostic imaging for over 70 years. 7 of their 9 sites across Long Island have dedicated Women’s Imaging Centers that combine physician expertise, state-of-the-art technology, and a patient-centered approach to care. These sites offer a complete array of women’s imaging services, including: 3D mammography, ultrasound, breast MRI, minimally invasive breast biopsy and DEXA bone density exams. Medical Arts Radiology is a member of the Independent Physician’s Association of Nassau/Suffolk (IPANS).


ALAMEDA, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, provided a summary of the data from its breast cancer diagnostic test that will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) in December.  The data will be presented by Karen B. Chapman, Ph.D., OncoCyte’s Vice President of Research, at 5:00pm CT on Friday, December 9th. The poster titled Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients discusses details of OncoCyte’s study, which collected serum samples from 100 women with suspicious diagnostic mammogram findings (primarily BI-RADS category 4) undergoing biopsy. The study evaluated the samples on the SOMAscan Assay 1.3k, which measures 1,310 different proteins. Statistical screening methods were used to identify markers distinguishing benign from malignant samples and combine them into a multi-biomarker algorithm. This study revealed a novel panel of serum protein biomarkers that may allow for the non-invasive and sensitive detection of breast cancer in BI-RADS category 4 patients.  A 15-marker model resulted in an AUC of 0.92 with a sensitivity of 90% and specificity of 76%. The Company is conducting a follow on multicenter study to further develop and verify these results in a larger set of prospectively collected patient samples. BI-RADS (Breast Imaging and Reporting Data System) is a scoring system developed by the American College of Radiologists to help clinicians assess the risk of cancer in women with a lump or mass.  BI-RADS 4 is the score given to a woman with a suspicious lump or mass. Each year approximately 38 million women in the U.S. undergo mammogram screenings. Mammograms detect suspicious lumps or masses in about 1.5 to 2 million of these women, who then require an invasive follow-on breast tissue biopsy to determine if the mass is malignant or benign. However, only about 20% of these biopsies result in a cancer diagnosis. Consequently, the majority of biopsies are not needed, and result in unnecessary pain, discomfort and anxiety to women as well as an estimated $2.8 billion annual cost to the healthcare system. OncoCyte is focused on developing a confirmatory diagnostic blood test that can be used as an adjunct to suspicious mammography results. “Our goal is to reduce the number of unnecessary breast biopsies that women have to undergo,” commented William Annett, President and Chief Executive Officer.  “The data from this initial study is encouraging, and our diagnostic test was able to distinguish between benign and cancerous masses. To validate these findings we are now in the process of conducting a larger study.  If successful, our test will address a patient population of approximately two million American women who have to have breast biopsies each year.” Breast cancer is the second most common cancer among US women. Current screening guidelines set forth by the American Cancer Society recommend screening mammography for the early detection of breast cancer in women at average risk. Specifically, guidelines call for annual mammography for asymptomatic women age 45 to 54 and once every two years for women age 55 and older. Suspicious screening mammograms are generally followed up with a diagnostic mammogram and sometimes by an MRI (Magnetic Resonance Image) or an ultrasound.  Ultimately, suspicious findings unresolved by imaging typically result in the recommendation of a breast biopsy. OncoCyte is primarily focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. This press release contains forward-looking statements.  Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) are forward-looking statements. These statements include those pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in “Risk Factors” found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as may be required by law.


SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced it has partnered with Hospital Services Limited (HSL), an established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM® Molecular Breast Imaging system in the United Kingdom, Ireland and the Channel Islands. Women are eligible for the United Kingdom’s NHS breast screening programme at age 50-79 years, with women being invited to be screened every three years.1 Similarly in Ireland, women 50-69 years-old are eligible for breast screenings every two years.2 Dense breast tissue not only increases the risk of developing breast cancer, but decreases the visibility of a cancer on conventional mammograms and other forms of anatomical imaging devices. Dense breast tissue and cancer both appear white on mammograms making it difficult to distinguish between the two—it’s like trying to find a snowflake in a snowstorm. This may lead to false negatives, unwarranted biopsies or delayed diagnoses.3 Ideal for dense breast tissue, MBI is a groundbreaking technology that significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective as a secondary screening method compared to ultrasound or MRI with far fewer false positives.4 Peer-reviewed clinical research reports the use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities.4 MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI. “We are pleased that through our collaboration with HSL, women with dense breasts in the UK, Ireland and the Channel Islands, will soon have access to the LumaGEM MBI technology,” said Philip Croxford, Gamma Medica President and CEO. “This partnership is the first step in Gamma Medica’s global expansion to increase awareness and access to clinical superior breast imaging technology worldwide. Leveraging HSL’s network enables Gamma Medica to continue to promote early detection on an international scale.” A breakthrough retrospective study, which complemented earlier published prospective clinical research, was published in the American Journal of Roentgenology’s August issue.5 This retrospective study monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent of these cancers were invasive and node negative, indicating they were detected at an early stage and therefore presented the patient with the likelihood of a better prognosis.6 “Hospital Services Limited distributes market-leading technology and we are thrilled to add Gamma Medica’s LumaGEM Molecular Breast Imaging to our product offerings for our clients,” said Dominic Walsh, CEO of Hospital Services Limited. “Introducing Gamma Medica to the European market will enable women outside of the United States to receive the early detection technology they need. We’re excited to be Gamma Medica’s partner in this endeavor.” Gamma Medica launched the Be Certain campaign in the United States to raise awareness about breast density and breast cancer screening options. By sharing patient and physician testimonials, breast density facts and statistics and the latest news relating to breast density and breast screenings, the educational website aims to provide the most accurate information for physicians, patients and caregivers. For more information about breast density and screening options, visit www.becertain.info. About Gamma Medica, Inc. Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging experienced by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com. About Hospital Services Limited Hospital Services Limited (HSL) is a leading provider of products & services to the healthcare sector in both Ireland and the UK. HSL’s Radiology division has over 50 years’ experience working within this diagnostic imaging arena. HSL offers unprecedented levels of quality products, services and technical assistance. HSL representatives with extensive imaging experience, supply products and support to all levels of medical staff with a major focus on providing quality service to the individual customer, whilst manufacturer trained engineers ensure equipment is maintained to exacting standards. HSL is committed to sourcing the latest technologies available to help provide peace of mind to patients and physicians alike while utilising cutting edge diagnostic tools. 1 Gov.uk, Breast Screening: Programme Overview, 2015. https://www.gov.uk/guidance/breast-screening-programme-overview 2 BreastCheck. http://www.breastcheck.ie/ 3 Mayo Clinic. Tests and Procedures Mammogram. http://www.mayoclinic.org/tests-procedures/mammogram/in-depth/dense-breast-tissue/art-20123968?pg=2 4 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 5 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 6 Shermis RB, Wilson KD, Doyle MT, Martin TS, Merryman D, Kudrolli H, Brenner RJ. Supplemental Breast Cancer Screening with Molecular Breast Imaging for Women with Dense Breast Tissue. American Journal of Roentgenology. 2016;207: 1-8. doi:10.2214/AJR15.15924.


News Article | February 22, 2017
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Breast Imaging Market: Trends Analysis and Forecasts up to 2022" report to their offering. Global Breast Imaging Markets expected to grow at a CAGR between 8.0% and 9.0% over the Forecast period 2016 to 2022. Breast imaging technologies have evolved and improved for the screening and detection of breast cancer over the years due to technological developments. The Digital breast imaging is technology is used in supplemental imaging to detect concerns with mammography including false positive rates and missed cancers. The Global Breast Imaging market is expected to be primarily driven by Factors such as Growing Prevalence of Breast Cancer, Increasing Awareness about Early Detection of Breast Cancer and Government Investments, and Funding for Breast Cancer Treatment. However, the growth in the global breast imaging market is likely to be restrained by factors such as high installation costs of breast imaging systems, side effects of radiation exposure, and errors in breast cancer screening and diagnosis. For more information about this report visit http://www.researchandmarkets.com/research/68qgbj/global_breast


The International Association of HealthCare Professionals is pleased to welcome Gale A. Sisney, MD, FACR, Diagnostic Radiologist, to their prestigious organization with her upcoming publication in The Leading Physicians of the World. Dr. Gale A. Sisney is a highly trained and qualified radiologist with an extensive expertise in all facets of her work, especially breast imaging. Dr. Sisney has been in practice for more than 23 years and is currently serving patients within Global Radiology Outreach in Madison, Wisconsin. She is also serving patients within Radiology Mammography International. Dr. Sisney attended the University of Illinois at Chicago, graduating with her Medical Degree in 1988. Following her graduation, she subsequently completed her Diagnostic Radiology residency at Northwestern University Medical School, before undertaking her fellowship training in Breast Imaging and Intervention at the Swedish Medical Center: Radiology Imaging Associates. She has earned the coveted title of Fellow of the American College of Radiology. In addition to her clinical practice, Dr. Sisney is a lecturer for Herzing University, providing education and training for medical imaging and radiation therapy professionals. To keep up to date with the latest advances in her field, Dr. Sisney maintains professional memberships with the American College of Radiology, the Radiological Society of North America, the Association for American Women Radiologists, the Society of Breast Imaging, the American Roentgen Ray Society, and the Wisconsin Radiological Society. With her wealth of experience and knowledge, Dr. Sisney has been published extensively, and has appeared on several media, radio, and television broadcasts. Dr. Sisney attributes her success to her persistence. Learn more about Dr. Sisney by reading her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit http://www.findatopdoc.com


News Article | February 15, 2017
Site: www.marketwired.com

MONTREAL, QUEBEC--(Marketwired - Feb. 10, 2017) - Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the "Company" or "Relevium") a consolidator of e-commerce assets in Health and Wellness in conjunction with its board of directors, is pleased to announce the addition of Dr. Tina Sampalis to the Company's Board of Directors. Tina Sampalis, M.D., Ph.D., is an oncology surgeon trained in physiology at McGill University in Montreal, medicine at the University of Patras (Greece), dermatology at Göttingen University (Germany) and Marselisborg University (Denmark), pediatric, general and oncology surgery at the University of Athens (Greece), graduate training (Ph.D.) in Surgical Research at the University of Athens and a second Ph.D. in Epidemiology and Experimental Surgery at McGill University. Dr. Sampalis' leading work in Nutraceuticals includes Neptune Technologies & Bioressources, where she discovered one of the primary reasons krill oil is so beneficial to human health: Phospholipids. Dr. Sampalis is the named inventor of Neptune's composition and application patents. As the former President of Acasti Pharma Inc. she led the development of a novel patented active pharmaceutical ingredient targeting the prevention and treatment of hypertriglyceridemia and cardio metabolic-disorders. She is the Founder and President of the AGOO Children's Health & Wellness Center, a state-of-the-art multidisciplinary comprehensive, pediatric-adolescent medical center and accredited McGill University teaching site in Quebec. Dr. Sampalis has received several international scholarships and awards for her work on the clinical implementation of retinols for skin and breast cancer, including the Helen Hutchison Award for geriatric medicine. Her work on scintimammography resulted in her appointment at the International Educational Speakers Bureau, the Canadian and U.S. Faculty of Medical Speakers for Breast Imaging. As an international scholar, Dr. Sampalis leads the development and implementation of innovative micro-invasive and stereotactic robotic surgical techniques for breast cancer, for which a U.S. and Canadian patent application has been filed. She is a member of the American Association of Naturopathic Medicine. Dr. Sampalis has published papers in multiple peer-reviewed publications. She was named one of the 10 most successful women in Quebec (Les Affaires, 18-24 September 2010) and one of the 100 most successful globally by the Princeton Global Network. Relevium Technologies Inc. (TSX.V - "RLV") President and CEO, Aurelio Useche, stated, "We are very honored to have Dr. Sampalis join our Company. The addition of Dr. Sampalis closes the value chain by providing deep expertise in scientific and evidence based nutraceutical and medical trends, which can be leveraged through the consolidation of e-commerce assets such as BioGanix as announced on December 22, 2016." Relevium is a TSX Venture listed issuer focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector, specifically under three important verticals: Pain Relief, Recovery and Performance. Relevium Technologies Inc. currently holds patented intellectual property for application of static magnetic fields on direct-to-consumer devices, which aid in decreasing pain, improving recovery time and enhancing overall physical performance. BioGanix (http://www.bioganix.com/) was founded with customer results in mind, to provide the best quality, best researched, and most potent formulas at competitive prices, while providing excellent and personal customer care. BioGanix puts our customers first, and do everything we can to keep them happy. BioGanix prides itself on using only the best and purest ingredients in our manufacturing processes. BioGanix only provides premium quality products, and doesn't cut any corners in manufacturing processes. All BioGanix products have been 3rd Party Laboratory tested and verified, and are manufactured in GMP Certified and FDA inspected facilities in the USA. BioGanix currently has over 16 of the best-selling dietary supplement products available, varying from trending weight loss products, to proven health supporting supplements that supports various processes in the body, including digestive health, heart health, brain health, blood sugar, as well as anti-aging supplements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward- looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor. On Behalf of the Board of Directors


CHICAGO--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced several 2016 achievements for its LumaGEM Molecular Breast Imaging system at this year’s Radiological Society of North America (RSNA) annual meeting (booth #2871). Over the past year, this MBI system has grown in national prominence and expanded its user base through a major educational campaign on breast density called Be Certain and by driving irrefutable clinical results featured in

Loading Breast Imaging collaborators
Loading Breast Imaging collaborators